Xenon Pharmaceuticals Inc. (XENE) 8-K Current Report: February 27, 2026
Filed: February 27, 2026
Health Care
Pharmaceutical PreparationsXenon Pharmaceuticals Inc. (XENE) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Xenon Pharmaceuticals Inc. 8-K Feb 27, 2026 Event Analysis
Item 8.01 · Other Events
- • ATM program refreshed with $400M capacity via new prospectus supplement filed Feb 27, 2026, superseding prior prospectus
- • Already sold $291M under existing Sales Agreement, leaving meaningful remaining capacity under the new $400M shelf
- • Sales agents are Jefferies and Stifel; shares sold at-market on an ongoing, opportunistic basis — continuous dilution risk for existing holders
- • Backed by S-3 shelf registration (File No. 333-281451) filed Aug 2024, giving XENE flexible, rapid access to equity capital markets
Other Xenon Pharmaceuticals Inc. 8-K Filings
Get deeper insights on Xenon Pharmaceuticals Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.